Corrigendum to “Subcutaneous interferon beta-1a 22/44 µg demonstrates comparable effectiveness versus teriflunomide in newly treated patients with multiple sclerosis. A study in a French nationwide cohort of Multiple Sclerosis: Observatoire Francais de la sclérose en plaques” [Multiple Sclerosis and Related Disorders, 37 (2020) 101598]